title: Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.
abstract: Evaluate if vascular normalization with an antiangiogenic monoclonal antibody improves detection of melanoma using fluorescently labeled antibody-based imaging.
  
  
  
  Preclinical.
  
  
  
  Panitumumab and control IgG were covalently linked to a near-infrared fluorescent probe (IRDye800CW). Immunodeficient mice with ear xenografts of melanoma cell lines (A375 and SKMEL5) were systemically injected (200 μg, tail vein) with either IgG-IRDye800CW, panitumumab-IRDye800CW, or a combination (bevacizumab [5mg/kg], administered 72 hours prepanitumumab-IRDye800CW) (n = 5). Primary tumors were imaged with open-field (LUNA, Novadaq, Toronto, Ontario, Canada) and closed-field (Pearl, LI-COR Biosciences, Lincoln, NB) imaging devices. Postresection, the concentration of labeled antibody within the tumor (μg/g) was calculated using normalized standards.
  
  
  
  The mean fluorescence within the melanoma tumors was greater for the combination group compared to panitumumab alone for both cell lines (P < 0.001). The tumor-to-background ratio (TBR) for the A375 tumors was greater for the combination (3.4-7.1) compared to the panitumumab alone (3.2-5.0) (P = 0.04). The TBR for SKMEL5 tumors was greater for the combination (2.4-6.0) compared to the panitumumab alone (2.2-3.9) (P = 0.02). Within A375 tumors, the concentration was lower for panitumumab (0.51 μg/g) compared to combination group (0.68 μg/g) (P = 0.036). Within SKMEL5 tumors, the concentration was lower for panitumumab (0.0.17 μg/g) compared to combination group (0.35 μg/g) (P = 0.048). Residual tumor (1.0-0.2 mg) could be differentiated from background in both panitumumab and combination groups. For both cell lines, panitumumab and combination groups had greater mean fluorescence of the tumor compared to control IgG.
  
  
  
  The addition of antiangiogenic therapy improves uptake of fluorescently labeled monoclonal antibodies within melanoma tumors. Clinical translation could improve detection of melanoma intraoperatively, reducing positive margins and sparing normal tissue.
  
  
  
  NA Laryngoscope, 126:E387-E395, 2016.
authors: Department of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
authors: Larissa
authors: L
authors: Sweeny
authors: the University of Alabama School of Medicine at Birmingham, Birmingham, Alabama, U.S.A.
authors: Andrew
authors: A
authors: Prince
authors: the Department of Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
authors: Neel
authors: N
authors: Patel
authors: Department of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
authors: Lindsay S
authors: LS
authors: Moore
authors: Department of Otolaryngology, Stanford University, Stanford, California, U.S.A.
authors: Eben L
authors: EL
authors: Rosenthal
authors: Department of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
authors: Brian B
authors: BB
authors: Hughley
authors: Department of Otolaryngology-Head and Neck Surgery, University of Alabama at Birmingham, Birmingham, Alabama, U.S.A.
authors: Jason M
authors: JM
authors: Warram
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D000911:Antibodies, Monoclonal; D001557:Benzenesulfonates; D000068258:Bevacizumab / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D005453:Fluorescence; D005456:Fluorescent Dyes; D064593:Heterografts; D007211:Indoles; D008545:Melanoma / Q000175:diagnosis*; D051379:Mice; D008819:Mice, Nude; D016513:Mice, SCID; D000077544:Panitumumab
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D001557:Benzenesulfonates; D005456:Fluorescent Dyes; C562366:IRDye 800CW; D007211:Indoles; D000068258:Bevacizumab; D000077544:Panitumumab
keywords: Cutaneous; antibody; fluorescence; head and neck; melanoma; optical imaging